abs236.txt	although	successes	in	cancer	immunotherapy	have	generated	considerableexcitement		this	form	of	treatment	has	been	largely	ineffective	in	patients	withpancreatic	ductal	adenocarcinoma	(pda)		mechanisms	that	contribute	to	the	poorantitumor	immune	response	in	pda	are	not	well	understood		here		we	demonstratedthat	cytokine	il35	is	a	major	immunosuppressive	driver	in	pda	and	potentiatestumor	growth	via	the	suppression	of	endogenous	antitumor	t-cell	responses		thegrowth	of	pancreatic	tumors	in	mice	deficient	for	il35	was	significantly	reduced	an	analysis	of	tumor-infiltrating	immune	cells	revealed	a	role	for	il35	in	theexpansion	of	regulatory	t	cells	and	the	suppression	of	cd4+	effector	t	cells		wealso	detected	a	robust	increase	in	both	the	infiltration	and	activation	ofcytotoxic	cd8+	t	cells		suggesting	that	targeting	il35	may	be	an	effectivestrategy	to	convert	pda	from	an	immunologically		cold		to		hot		tumor		althoughpda	is	typically	resistant	to	anti-pd-1	immunotherapy		we	demonstrated	robustsynergistic	reduction	in	tumor	growth	when	il35	deficiency	was	combined	withanti-pd-1	treatment		these	findings	provide	new	insight	into	the	function	of	il35in	the	pathogenesis	of	pancreatic	cancer	and	underscore	the	potentialsignificance	of	il35	as	a	therapeutic	target	for	use	in	combination	immunotherapyapproaches	in	this	deadly	malignancy		cancer	immunol	res		6(9)		1014-24		Â©2018aacr	
